Reducing the risk of Adeno-Associated Virus (AAV) vector mobilization with AAV type 5 vectors

F. Curtis Hewitt, Chengwen Li, Steven J. Gray, Shelley Cockrell, Michael Washburn, R. Jude Samulski

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Current adeno-associated virus (AAV) gene therapy vectors package a transgene flanked by the terminal repeats (TRs) of AAV type 2 (AAV2). Although these vectors are replication deficient, wild-type (wt) AAV2 prevalent in the human population could lead to replication and packaging of a type 2 TR (TR2)-flanked transgene in trans during superinfection by a helper virus, leading to "mobilization" of the vector genome from treated cells. More importantly, it appears likely that the majority of currently characterized AAV serotypes as well as the majority of new novel isolates are capable of rescuing and replicating AAV2 vector templates. To investigate this possibility, we flanked a green fluorescent protein transgene with type 2 and, the most divergent AAV serotype, type 5 TRs (TR2 or TR5). Consistent with AAV clades, AAV5 specifically replicated TR5 vectors, while AAV2 and AAV6 replicated TR2-flanked vectors. To exploit this specificity, we created a TR5 vector production system for Cap1 to Cap5. Next, we showed that persisting recombinant AAV genomes flanked by TR2s or TR5s were mobilized in vitro after addition of the cognate AAV Rep (as well as Rep6 for TR2) and adenoviral helper. Finally, we showed that a cell line containing a stably integrated wt AAV2 genome resulted in mobilization of a TR2-flanked vector but not a TR5-flanked vector upon adenoviral superinfection. Based on these data and the relative prevalence of wt AAV serotypes in the population, we propose that TR5 vectors have a significantly lower risk of mobilization and should be considered for clinical use.

Original languageEnglish (US)
Pages (from-to)3919-3929
Number of pages11
JournalJournal of Virology
Volume83
Issue number8
DOIs
StatePublished - Apr 1 2009

Fingerprint

Dependovirus
terminal repeat sequences
Terminal Repeat Sequences
Transgenes
transgenes
Superinfection
serotypes
Genome
genome
Helper Viruses
gene therapy
Product Packaging
Green Fluorescent Proteins
green fluorescent protein
human population
Genetic Therapy
Population
packaging
production technology

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Reducing the risk of Adeno-Associated Virus (AAV) vector mobilization with AAV type 5 vectors. / Hewitt, F. Curtis; Li, Chengwen; Gray, Steven J.; Cockrell, Shelley; Washburn, Michael; Samulski, R. Jude.

In: Journal of Virology, Vol. 83, No. 8, 01.04.2009, p. 3919-3929.

Research output: Contribution to journalArticle

Hewitt, F. Curtis ; Li, Chengwen ; Gray, Steven J. ; Cockrell, Shelley ; Washburn, Michael ; Samulski, R. Jude. / Reducing the risk of Adeno-Associated Virus (AAV) vector mobilization with AAV type 5 vectors. In: Journal of Virology. 2009 ; Vol. 83, No. 8. pp. 3919-3929.
@article{14a4fe334f3542ad8de2c1758e2181d8,
title = "Reducing the risk of Adeno-Associated Virus (AAV) vector mobilization with AAV type 5 vectors",
abstract = "Current adeno-associated virus (AAV) gene therapy vectors package a transgene flanked by the terminal repeats (TRs) of AAV type 2 (AAV2). Although these vectors are replication deficient, wild-type (wt) AAV2 prevalent in the human population could lead to replication and packaging of a type 2 TR (TR2)-flanked transgene in trans during superinfection by a helper virus, leading to {"}mobilization{"} of the vector genome from treated cells. More importantly, it appears likely that the majority of currently characterized AAV serotypes as well as the majority of new novel isolates are capable of rescuing and replicating AAV2 vector templates. To investigate this possibility, we flanked a green fluorescent protein transgene with type 2 and, the most divergent AAV serotype, type 5 TRs (TR2 or TR5). Consistent with AAV clades, AAV5 specifically replicated TR5 vectors, while AAV2 and AAV6 replicated TR2-flanked vectors. To exploit this specificity, we created a TR5 vector production system for Cap1 to Cap5. Next, we showed that persisting recombinant AAV genomes flanked by TR2s or TR5s were mobilized in vitro after addition of the cognate AAV Rep (as well as Rep6 for TR2) and adenoviral helper. Finally, we showed that a cell line containing a stably integrated wt AAV2 genome resulted in mobilization of a TR2-flanked vector but not a TR5-flanked vector upon adenoviral superinfection. Based on these data and the relative prevalence of wt AAV serotypes in the population, we propose that TR5 vectors have a significantly lower risk of mobilization and should be considered for clinical use.",
author = "Hewitt, {F. Curtis} and Chengwen Li and Gray, {Steven J.} and Shelley Cockrell and Michael Washburn and Samulski, {R. Jude}",
year = "2009",
month = "4",
day = "1",
doi = "10.1128/JVI.02466-08",
language = "English (US)",
volume = "83",
pages = "3919--3929",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Reducing the risk of Adeno-Associated Virus (AAV) vector mobilization with AAV type 5 vectors

AU - Hewitt, F. Curtis

AU - Li, Chengwen

AU - Gray, Steven J.

AU - Cockrell, Shelley

AU - Washburn, Michael

AU - Samulski, R. Jude

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Current adeno-associated virus (AAV) gene therapy vectors package a transgene flanked by the terminal repeats (TRs) of AAV type 2 (AAV2). Although these vectors are replication deficient, wild-type (wt) AAV2 prevalent in the human population could lead to replication and packaging of a type 2 TR (TR2)-flanked transgene in trans during superinfection by a helper virus, leading to "mobilization" of the vector genome from treated cells. More importantly, it appears likely that the majority of currently characterized AAV serotypes as well as the majority of new novel isolates are capable of rescuing and replicating AAV2 vector templates. To investigate this possibility, we flanked a green fluorescent protein transgene with type 2 and, the most divergent AAV serotype, type 5 TRs (TR2 or TR5). Consistent with AAV clades, AAV5 specifically replicated TR5 vectors, while AAV2 and AAV6 replicated TR2-flanked vectors. To exploit this specificity, we created a TR5 vector production system for Cap1 to Cap5. Next, we showed that persisting recombinant AAV genomes flanked by TR2s or TR5s were mobilized in vitro after addition of the cognate AAV Rep (as well as Rep6 for TR2) and adenoviral helper. Finally, we showed that a cell line containing a stably integrated wt AAV2 genome resulted in mobilization of a TR2-flanked vector but not a TR5-flanked vector upon adenoviral superinfection. Based on these data and the relative prevalence of wt AAV serotypes in the population, we propose that TR5 vectors have a significantly lower risk of mobilization and should be considered for clinical use.

AB - Current adeno-associated virus (AAV) gene therapy vectors package a transgene flanked by the terminal repeats (TRs) of AAV type 2 (AAV2). Although these vectors are replication deficient, wild-type (wt) AAV2 prevalent in the human population could lead to replication and packaging of a type 2 TR (TR2)-flanked transgene in trans during superinfection by a helper virus, leading to "mobilization" of the vector genome from treated cells. More importantly, it appears likely that the majority of currently characterized AAV serotypes as well as the majority of new novel isolates are capable of rescuing and replicating AAV2 vector templates. To investigate this possibility, we flanked a green fluorescent protein transgene with type 2 and, the most divergent AAV serotype, type 5 TRs (TR2 or TR5). Consistent with AAV clades, AAV5 specifically replicated TR5 vectors, while AAV2 and AAV6 replicated TR2-flanked vectors. To exploit this specificity, we created a TR5 vector production system for Cap1 to Cap5. Next, we showed that persisting recombinant AAV genomes flanked by TR2s or TR5s were mobilized in vitro after addition of the cognate AAV Rep (as well as Rep6 for TR2) and adenoviral helper. Finally, we showed that a cell line containing a stably integrated wt AAV2 genome resulted in mobilization of a TR2-flanked vector but not a TR5-flanked vector upon adenoviral superinfection. Based on these data and the relative prevalence of wt AAV serotypes in the population, we propose that TR5 vectors have a significantly lower risk of mobilization and should be considered for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=64049093048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049093048&partnerID=8YFLogxK

U2 - 10.1128/JVI.02466-08

DO - 10.1128/JVI.02466-08

M3 - Article

C2 - 19211760

AN - SCOPUS:64049093048

VL - 83

SP - 3919

EP - 3929

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

ER -